Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
2015/07/27 by R B Laprairie, Robert B. Laprairie, Amina M. Bagher +5 · 34 citations
Medicine · Neuroscience · Biochemistry, Genetics and Molecular Biology · #Cannabis and Cannabinoid Research #Neuroscience of respiration and sleep #Pharmacological Receptor Mechanisms and Effects
paper · pdf · doi:10.1111/bph.13250
Abstract
BACKGROUND AND PURPOSE: Cannabidiol has been reported to act as an antagonist at cannabinoid CB1 receptors. We hypothesized that cannabidiol would inhibit cannabinoid agonist activity through negative allosteric modulation of CB1 receptors. EXPERIMENTAL APPROACH: Internalization of CB1 receptors, arrestin2 recruitment, and PLCβ3 and ERK1/2 phosphorylation, were quantified in HEK 293A cells heterologously expressing CB1 receptors and in the STHdh(Q7/Q7) cell model of striatal neurons endogenously expressing CB1 receptors. Cells were treated with 2-arachidonylglycerol or Δ(9)-tetrahydrocannabinol alone and in combination with different concentrations of cannabidiol. KEY RESULTS: Cannabidiol reduced the efficacy and potency of 2-arachidonylglycerol and Δ(9)-tetrahydrocannabinol on PLCβ3- and ERK1/2-dependent signalling in cells heterologously (HEK 293A) or endogenously (STHdh(Q7/Q7)) expressing CB1 receptors. By reducing arrestin2 recruitment to CB1 receptors, cannabidiol treatment prevented internalization of these receptors. The allosteric activity of cannabidiol depended upon polar residues being present at positions 98 and 107 in the extracellular amino terminus of the CB1 receptor. CONCLUSIONS AND IMPLICATIONS: Cannabidiol behaved as a non-competitive negative allosteric modulator of CB1 receptors. Allosteric modulation, in conjunction with effects not mediated by CB1 receptors, may explain the in vivo effects of cannabidiol. Allosteric modulators of CB1 receptors have the potential to treat CNS and peripheral disorders while avoiding the adverse effects associated with orthosteric agonism or antagonism of these receptors.
Cited by
- Developing a functional non-animal CNS stress model utilizing long-term potentiation with human iPSC-cortical neurons to evaluate therapeutics
- Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial
- Exploring natural non-cannabis sources of cannabinoid-based compounds: a review
- Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery
- Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural and health outcomes: A systematic scoping review of multi-disciplinary studies
- Cannabidiol alleviates neuroinflammation and attenuates neuropathic pain via targeting FKBP5
- Improved drug delivery across the blood-brain barrier through post-insertion functionalization of lipid nanocapsules with cannabidiol using click chemistry
- Single cannabidiol administration affects anxiety-, obsessive compulsive-, object memory-, and attention-like behaviors in mice in a sex and concentration dependent manner
- The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence
- Molecular Targets of the Phytocannabinoids: A Complex Picture. [europepmc]
- The endocannabinoid system as a target for novel anxiolytic drugs. [europepmc]
- Cannabis use during pregnancy: Pharmacokinetics and effects on child development. [europepmc]
- Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB 2 Receptors. [europepmc]
- Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. [europepmc]
- An overview of the cannabinoid type 2 receptor system and its therapeutic potential. [europepmc]
- Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. [europepmc]
- Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. [europepmc]
- Cannabinoid Delivery Systems for Pain and Inflammation Treatment. [europepmc]
- The neuropsychopharmacology of cannabis: A review of human imaging studies. [europepmc]
- Cannabinoids and Pain: New Insights From Old Molecules. [europepmc]
- Cannabinoid Ligands Targeting TRP Channels. [europepmc]
- Cannabidiol Adverse Effects and Toxicity. [europepmc]
- Antioxidative and Anti-Inflammatory Properties of Cannabidiol. [europepmc]
- Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. [europepmc]
- Immune Responses Regulated by Cannabidiol. [europepmc]
- Cannabinoids and Cannabinoid Receptors: The Story so Far. [europepmc]
- Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products. [europepmc]
- Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. [europepmc]
- Review of the Endocannabinoid System. [europepmc]
- Diversity of molecular targets and signaling pathways for CBD. [europepmc]
- Cannabidiol: pharmacology and therapeutic targets. [europepmc]
- Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. [europepmc]
- In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. [europepmc]
- G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. [europepmc]
Related